ImmuPharma (LON:IMM) Shares Down 4.8% – Should You Sell?

ImmuPharma plc (LON:IMM)’s stock price dropped 4.8% during trading on Wednesday . The stock traded as low as GBX 2.66 ($0.04) and last traded at GBX 2.85 ($0.04). Approximately 5,267,162 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 8,756,827 shares. The stock had previously closed at GBX 3 ($0.04).

ImmuPharma Stock Performance

The firm has a market cap of £12.06 million, a P/E ratio of -4.91 and a beta of 1.53. The firm’s fifty day moving average price is GBX 2.90 and its 200 day moving average price is GBX 2.73.

ImmuPharma (LON:IMM) last posted its quarterly earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, analysts expect that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.